Press release: Uppsala,
First quarter, January-
- Net sales amounts to KSEK 0 (0)
- Earnings after financial items amounts to KSEK -13,638 (-9,944)
-
Earnings per share amounts to
SEK -0.02 (-0.03)
"The safety profile demonstrated by LIB-01 in the Phase 1 study is very good, and to be honest, one can hardly get better results from a safety study. And thanks to exploratory measurements, we have managed to identify an efficacy signal, even though it was not the main purpose of the study. We see that the increased erectile function for some has been experienced 28 days after first dosing", says
Significant events during the quarter
- Positive results from the first part of the phase 1 study are presented; showing a very good safety profile, no serious side effects, and a good exposure in the body
- Patent application is filed for a new manufacturing method of the starting material through cell culture
-
The preclinical research results are presented at the
European Society for Sexual Medicine
Significant events after the quarter
- Results from the final part of the phase 1 clinical trial show a very good safety profile and an efficacy signal is detected. Improved erectile function is reported through self-assessment forms and measurements, for some it persisted after 28 days at the end of the study
- Preparations for clinical phase 2a begin; study drug is manufactured and partner to conduct the study is procured
For further information, please contact:
Phone: +46 72 502 1010 Phone: +46 76 109 0000
E-mail: elin.trampe@dicot.se E-mail: bjorn.petersson@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at
Dicot is listed on
This disclosure contains information that
https://news.cision.com/dicot-ab--publ-/r/dicot-presents-interim-report-q1-2024,c3973005
https://mb.cision.com/Main/17172/3973005/2778307.pdf
https://mb.cision.com/Public/17172/3973005/8479474164b8b3e6.pdf
(c) 2024 Cision. All rights reserved., source